None listed
Conditions
Interventions
Intervention1: 1.Test product 1- New Liftactiv B3 Melasyl Serum (689189 92): To be applied twice daily for 12 weeks
Control Intervention1: 2.Test Product 2- Liftactiv serum without actives ingredients
Sponsors
VICHY LABORATOIRES
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects with various skin types, including normal, dry, oily, and combination, 2. 50% of the subjects with self-declared sensitive skin 3. Subjects with phototype III to VI (where all phototype will be enrolled in equal proportion for both the groups). 4. Subjects with at least 2 epidermal spots that can be measured no dermal pigmentation as confirmed by Dermascopy/ wood’s lamp. 5. Subjects with a minimum hair length of 10-15 cm. 6. Subjects having mild active acne (less than 10 retentional and 5 inflammatory lesions). 7. Subjects with mild to moderate facial post acne hyperpigmentation. 8. Subjects who agree not to change their lifestyle during the study period. 9. Subjects free of excessive hair, acne, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions on the face as determined by the dermatologist. 10. Subject who agrees not to use any other product/treatment/home remedy/ except the provided product on their face during the study period other than the test product. 11. Subjects who agree not to carry out bleaching or any other procedures including facial etc. on face during the study period. 12. Subjects who agree not to expose to excessive sun light (sun exposure not more than half an hour daily and during that time use of umbrella to cover face). 13. Subjects willing to give a voluntary written informed consent, photography release and agree to come for regular follow-up. 14. Subjects willing to abide by and comply with the study protocol
Exclusion criteria
Exclusion criteria: 1.Subjects suffering from severe acne. 2.Subjects under topical or systemic retinoids. 3.Subjec.ts under systemic immunosuppressants 4. Subjects under active treatment of PIHP (including topicals or procedures) within the last 3 months. 5. Subjects treated with facial procedures within the last 3 months 6. Subjects diagnosed with Dermal melanosis by Dermascope 7. Subjects diagnosed with Lichen Planus Pigmentosus. 8. Subject with any other signs of significant local irritation or skin disease. 9. Subject currently taking any medication, which the Investigator believes may influence the interpretation of the data. 10. Subject having clinically significant systemic or cutaneous disease, chronic illness or had major surgery in the last year. 11. Subjects who do not agree to remove all jewellery on/around face (e.g., necklace, earrings, if possible, nose ring), during VISIA CR imaging. 12. Subjects having hair style which covers almost the entire forehead 13. Subjects undergoing any treatment of any skin condition on their face 14. Subjects not willing to discontinue other topical facial products. 15. Subject allergic or sensitive to bar, cleansing products, cosmetics, creams/lotions, artificial jewellery or anything else. 16. Subjects who are pregnant and lactating 17. Subjects on any medical treatment either systemic/topical in the past 1 month or currently taking medication including food supplements. 18. Subjects with skin allergy, history of atopic dermatitis or psoriasis 19. Subjects who have participated in any other clinical trial in the last 3 months. 20. Subjects using oral contraceptive pills or hormonal implants as birth control measures during the study 21. Subjects who have undergone treatment with Botox/filler /bio stimulatory molecules injection. 22. Subjects not able to provide Informed Consent and comply with the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate and compare the efficacy of the test products in improving the PAHPI score in 12 weeks compared to the baselineTimepoint: baseline, Month1 , Month2, Month3 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To evaluate and compare the effectiveness of the test products in improving IGA scores.Timepoint: baseline, Month1 , Month2, Month3 | — |
Countries
India
Contacts
Public ContactDr Mukta Sachdev
MS Clinical Research Pvt Ltd
Outcome results
None listed